ERLONAT
DESCRIPTION
Erlonat 150mg tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat 150mg is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.
Erlonat 150mg tablets are prescription medicine, used only by the patients who have valid prescription
 |
| Erlonat 150mg |
INDICATION AND USAGE
Erlonat 150mg is primarily indicated for; Non small cell lung cancer: Erlonat 150mg tablet is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlonat is involved in the treatment of non-small cell lung cancer patients whose cancer cells Erlonat 150mg tablets containing epidermal growth factor receptors on their surface. Erlonat 150mg is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlonat Erlonat 150mg tablets is used in combination with gemcitabine. In this condition Erlonat is involved as first line treatment.
WARNING
Some of the adverse effects occur while treating with Erlonat 150mg tablets; Interstitial lung disease Renal impairmentErlonat 150mg tablets Hepatic toxicity with liver failure Gastrointestinal perforation Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia Hemorrhage Ocular Erlonat 150mg tablets disorders Embryo fetal toxicity
ERLONAT PHARMACOLOGY
Erlonat has pharmacological effectsErlonat 150mg tablets like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factorErlonat 150mg tablets receptor. This EGFR is occursErlonat 150mg tablets on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.
ERLONAT ADME PROPERTY
ABSORPTION
The peak plasma concentration Erlonat 150mg tablets time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its bioavailability to 100%. The Erlotinib 1 Erlonat 150mg tablets solubility is dependsErlonat 150mg tablets upon pH level. The reduction in solubility causes elevation of the Erlonat 150mg tablets pH levels. Smoking should Erlonat 150mg tablets be avoided during the treatment with Erlonat 150mg , causes decreasing the exposure of Erlotinib.
DISTRIBUTION
Volume of distribution Erlonat 150mg tablets of Erlotinib is 232L Human protein binding to Erlotinib 150mg tablet is occurs as 93%.
METABOLISM
The metabolism of Erlotinib isErlonat 150mg tablets occurs by CYP3A4
ELIMINATION
The route of elimination of ErlotinibErlonat 150mg tablets metabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.
PRODUCT DETAILS
Brand : Erlonat
Ingredients : Erlotinib
Strength : 150mg
Manufactured : Natco
Package : 30 Tablets
DOSAGE ADMINISTRATION
DOSAGE MANAGEMENT
In NSCLC: Erlonat 150mg tablets The recommended dosage is 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlonat is 100mg should be taken as a Erlonat 150mg tablets single dose by administering on an empty stomachErlonat 150mg tablets by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Interstitial lung disease, pulmonary failure: Discontinue the Erlonat therapy In severe hepatic failure: Stop the therapy permanently
SIDE EFFECTS
SOME SERIOUS ADVERSE EFFECT
Renal failure Erlonat 150mg tablets Liver toxicity with failure Gastrointestinal perforations Ocular disorders HemorrhageErlonat 150mg tablets Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia
Rash Diarrhea Erlonat 150mg tablets Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Chest pain, arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while Erlonat 150mg tablets combining with lipid lowering drugs
DRUG INTERCTION
CYP3A4 INHIBITORS:
Concomitant use of Erlonat 150mg tablet with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir, Erlonat 150mg tablets posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) Erlonat 150mg tablets causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlonat .
IN CYP3A4 INDUCERS:
In combination ofErlonat 150mg tablets Erlonat with CYP3A4Erlonat 150mg tablets inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeuticErlonat 150mg tablets effect of Erlonat .
CYP1A2 INDUCERS & CIGARETTE SMOKING:
Both are decreasingErlonat 150mg tablets the exposure of Erlotinib, while concomitant with Erlonat .
GASTRIC REGULATORS:
While concomitant Erlonat 150mg tablets with gastric regulators like proton pump inhibitors, H2 receptors antagonist or antacids, causes depletion of Erlotinib Erlonat 150mg tablets exposure leads to loss of therapeutic effect of Erlotinib.
ANTICOAGULANTS:
In combination of Erlonat 150mg tablets Erlonat with warfarin, causes increasing international normalizedErlonat 150mg tablets ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.
Email id :millionhealthpharmaceuticals@gmail.com
Contact us :+91-9940472902
No comments:
Post a Comment